The Celiac Disease Foundation, the nation’s leading disease advocacy organization for celiac disease, announces the appointment of officers to its Board of Directors.
Continue ReadingIn partnership with Celiac Cruise, the Celiac Disease Foundation was proud to embark on the inaugural sailing aboard Royal Caribbean’s Mariner of the Seas, January 17-20, 2020, and strengthen community relationships in gluten-free paradise.
Continue ReadingOn December 11, 2019, CEO Marilyn G. Geller was with Senator Blumenthal's legislative staff as Senator Richard Blumenthal (D-CT) introduced S.3021: Gluten in Medicine Disclosure Act of 2019 to the Senate. The Celiac Disease Foundation is proud to be a partner in this effort.
Continue ReadingMikey’s, maker of gluten-free baked goods and hand-held pockets, announces sponsorship with the Celiac Disease Foundation, the preeminent nonprofit dedicated to accelerating diagnosis, treatments, and a cure for celiac disease.
Continue Reading2020 is starting out BIG, with the Celiac Disease Foundation hosting the National Celiac Disease Patient Advocacy Summit on February 27, 2020, in Washington, DC. Apply today to attend.
Continue ReadingResearchers at the Mucosal Immunology and Biology Research Center (MIBRC) at Massachusetts General Hospital, led by Stefania Seger and CDF Medical Advisory Board member Alessio Fasano, have created 3-D, miniature models of the intestines in order to research celiac disease.
Continue ReadingHappy New Year! With gratitude, we recognize your thoughtful support and contributions. Thanks to your continued generosity in 2020, we will continue to lead the fight towards treatments and a cure.
Continue ReadingAfter decades of pleading with our federal government to take celiac disease as seriously as it does other diseases with comparable patient impact, yesterday, the U.S. House and Senate each passed, and President Trump has signed, the FY2020 Federal budget resolution.
Continue ReadingImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe…
Continue ReadingAs I return to Los Angeles, I would like to take a moment to share with you some of the highlights of our productive two days in Washington, DC. Your…
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...